The Prevalence of Metabolic Syndrome, Scoring, and Comparison in People With and Without COPD: Evidence from Shahrekord PERSIAN Cohort Study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Kiani FZ;Kiani FZ; Ahmadi A; Ahmadi A
  • Source:
    Metabolic syndrome and related disorders [Metab Syndr Relat Disord] 2022 May; Vol. 20 (4), pp. 224-233. Date of Electronic Publication: 2022 Feb 18.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 101150318 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-8518 (Electronic) Linking ISSN: 15404196 NLM ISO Abbreviation: Metab Syndr Relat Disord Subsets: MEDLINE
    • Publication Information:
      Original Publication: Larchmont, NY : Mary Ann Liebert, Inc., c2003-
    • Subject Terms:
      Metabolic Syndrome*/complications ; Metabolic Syndrome*/diagnosis ; Metabolic Syndrome*/epidemiology ; Pulmonary Disease, Chronic Obstructive*/complications ; Pulmonary Disease, Chronic Obstructive*/diagnosis ; Pulmonary Disease, Chronic Obstructive*/epidemiology; Adult ; Cohort Studies ; Female ; Humans ; Prevalence ; Prospective Studies ; Risk Factors
    • Abstract:
      Background: Comorbidities are common in patients with chronic obstructive pulmonary diseases (COPDs), including metabolic syndrome (MetS). This study aimed to determine the prevalence of MetS and its components in people with and without COPD. Methods: This population-based study was performed on 6961 adults in the Shahrekord Prospective Epidemiological Research Studies in Iran. Data collection, spirometry, and COPD diagnosis were performed according to the cohort protocol from 2015 to 2019. The data were analyzed by two independent sample t -tests, analysis of covariance, chi-square, and odds ratio (OR) with 95% confidence interval (95% CI) in logistic regression models. P value <0.05 was considered statistically significant. All analyses were conducted using Stata Statistical Software Release 16 (Stata Corp., College Station, TX). Results: The prevalence of MetS in patients with and without COPD was 28.4% and 31%, respectively. The most common components of MetS in people with COPD were low high-density lipoprotein cholesterol (47.4%), waist circumference (43.9%), and high fasting plasma glucose (39.3%). There was a statistically significant difference in the frequency of respiratory dysfunction between people with and without MetS. Being older than 60 (OR = 2.20, 95% CI: 1.72-2.80), female (OR = 1.36, 95% CI: 1.49-1.97), obese (OR = 11.17, 95% CI: 9.02-13.62), and uneducated (OR = 1.80, 95% CI: 1.49-2.17), and living in urban areas (OR = 1.96, 95% CI: 1.64-2.35) are stronger predictors of MetS in this population. Conclusion: There was no significant difference in the prevalence of MetS between patients with and without COPD. Spirometry parameters and respiratory problems were significant in subjects with and without MetS.
    • Contributed Indexing:
      Keywords: PERSIAN cohort; chronic obstructive; metabolic syndrome; pulmonary disease
    • Subject Terms:
      Pulmonary Disease, Chronic Obstructive, Severe Early-Onset
    • Publication Date:
      Date Created: 20220218 Date Completed: 20220520 Latest Revision: 20220601
    • Publication Date:
      20240105
    • Accession Number:
      10.1089/met.2021.0060
    • Accession Number:
      35180365